Affimed (NASDAQ:AFMD) Shares Acquired by Intellectus Partners LLC

Intellectus Partners LLC raised its position in shares of Affimed (NASDAQ:AFMD) by 12.2% in the third quarter, HoldingsChannel reports. The firm owned 94,361 shares of the biopharmaceutical company’s stock after acquiring an additional 10,250 shares during the period. Intellectus Partners LLC’s holdings in Affimed were worth $317,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Choreo LLC bought a new position in Affimed during the 2nd quarter valued at $54,000. 30.82% of the stock is owned by institutional investors.

Affimed Stock Down 4.7 %

Shares of AFMD opened at $3.48 on Friday. The company has a 50-day moving average of $3.49 and a two-hundred day moving average of $4.52. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a one year low of $2.92 and a one year high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. As a group, equities analysts anticipate that Affimed will post -4.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Friday. Finally, Stifel Nicolaus reduced their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Affimed presently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.